Additionally, APOA-I is relevant throughout the entire stage of AD, and a substantial body of research has already demonstrated its protective effects against neurodegenerative diseases, making it a key substance that indicates early diagnosis and treatment for AD. Here, APOA1 is linked to neurodegenerative disease.